Which are the top 10 NZX healthcare stocks?

Summary

  • NZ’s healthcare segment is one of the prime drivers to boost the country’s economic progress and development.
  • Its medical device and pharmaceutical markets are backed by strong clinical trials and huge levels of investment in research and development.
  • Despite the monster pandemic, NZ's healthcare segment remained resilient and continued to make advancements.

New Zealand has one of the most advanced healthcare sectors in the world. Most of the patients rescheduled bookings and consulted doctors online or over the phone amid lockdowns and restrictions, yet the healthcare industry remained resilient to negative impacts of the pandemic.

As per reports, in March 2020, the country’s healthcare and social assistance industry had a GDP of about NZ$14.8 billion and the sector employed about 253,000 salary or wage earners.

Moreover, both NZ’s pharmaceutical market as well as medical devices market are some of the prominent markets in the Southwestern Pacific region, which is forecasted to reach around NZ$1.47 billion and NZ$1.59 billion, respectively, in 2025, aided by high levels of R&D and solid clinical trial environment.

Amid the given backdrop, let us look at the top 10 NZX stocks from the healthcare sector.

Source: Copyright © 2021 Kalkine Media

Summerset Group Holdings Limited (NZX:SUM)

To begin with, we would take a peek at Summerset Group Holdings Limited. It is one of the most respected and leading operators of the retirement villages and aged care sector in the country. Headquartered in Wellington, the Company operates 29 retirement villages across the country, catering to 6,000 people and offers independent living, and a varied programme of activities and events.

In its recently held Annual Shareholder Meeting, authorisation was given to the Board to fix the auditors’ renumeration. Moreover, James Ogden and Dr Marie Bismark were re-elected as directors.

On 9 July, by the end of the trading session, Summerset Group Holdings fell by 0.52% at NZ$13.280.

Must Read: Why are 5 NZX50-listed shares trending during the market session?

TruScreen Group Limited (NZX:TRU)

Functioning as a medical device company, TruScreen Group Limited manufacturs a cervical screening device known as TruScreen Ultra, thereby helping to improve the wellbeing of millions of women around the world. It has recently notified that its Annual General Meeting of Shareholders is scheduled for 7 September and would be held virtually. Moreover, it has urged its shareholders to send nominations for the re-election and appointment of Directors, which would close on 21 July.

On 9 July, TruScreen Group traded flat at NZ$0.070 by the end of the trading session.

Don’t Miss Reading: Are these 6 NZX stocks the biggest movers and shakers of the day?

Arvida Group Limited (NZX:ARV)

Coming up next is Arvida Group Limited, which also provides retirement and rest homes for the aged Kiwis. Recently, a resolution was approved for the re-election of Susan Peterson as its Director. Moreover, the maximum total remuneration payable to all Directors has been increased to NZ$640,000 p.a. i.e., by NZ $140,000 p.a. in its recently held Annual Meeting.

On 9 July, Arvida Group gained by 0.47% at NZ$2.130, by the end of the trading session.

Should Read: Why to explore 3 hot NZX dividend stocks in June 2021?

AFT Pharmaceuticals Limited (NZX:AFT)

We would now be looking at AFT Pharmaceuticals Limited, which is based in Auckland and manufactures, licenses, and sells pharmaceutical products worldwide. It has recently notified about the launch of its novel analgesic medicine, Maxigesic® IV, by its licensee Ever Pharma across Germany and Austria.

It is noted that AFT has licensed its pain reliever medicine in 100 countries and has filed for registration in other 24 countries across the globe.

AFT Pharmaceuticals rose by 1.33%, at NZ$4.580, by the end of the trading session on 9 July.

Can’t Miss Reading: Would Maxigesic® IV’s launch in Germany and Austria strengthen AFT’s presence in Europe?

Oceania Healthcare Limited (NZX:OCA)

Oceania Healthcare Limited is one of the leading providers of healthcare services in New Zealand, which not only offers independent living and rest homes but also provides dementia and palliative care services. In June, the Company had organised its Annual Shareholders Meeting, wherein it highlighted that NPAT and EBITDA for the 10 months ended 31 March 2021 were up 4% and 8%, respectively, on pcp.

Further, in March 2021, OCA had successfully completed an equity raise of NZ$100 million. Resolutions were also passed for the re-election of Directors of the Company.

On 9 July, by the end of the trading session, Oceania Healthcare, remained unchanged at NZ$1.510.

Interesting Read: How NZX dividend stocks are managing healthy payouts amid low-interest rate scenario

Rua Bioscience Limited (NZX:RUA)

Next in line is an NZ-based pharmaceutical company, Rua Bioscience Limited. It was established in 2017 and is a pioneer in NZ’s medicinal cannabis segment. Both RUA and a prominent NZ University have announced to undertake a research programme to explore the application of hyperspectral technology in the field of medicinal cannabis. If the technology works, RUA would be well placed to enter the country’s NZ$2.5-billion booming agritech sector.

Rua Bioscience traded flat at NZ$0.410 by the end of the trading session on 9 July.

Read: NZ Healthcare To Receive Structural Reform; 5 Related NZX Stocks- TRU, AFT, FPH, RUA, BLT

Cannasouth Limited (NZX:CBD)

Another company that develops medicinal cannabis products is Cannasouth Limited. Recently, the Company had entered into two conditional agreements to buy out the remaining stakes in its cultivation and manufacturing JV businesses.

  • Cannasouth Cultivation Limited’s balance acquisition of 50% stake for a purchase price amounting to NZ$3,540,000.
  • Obtaining the remaining 40% stake in Midwest Pharmaceutics NZ Limited for a purchase price of NZ$1,026,000.

On 9 July, by the end of the trading session, Cannasouth dropped by 1.05% at NZ$0.470.

Also Read: Which are the 10 hottest NZX-listed penny stocks?

Blis Technologies Limited (NZX:BLT)

We would now be looking at Blis Technologies Limited. The Company has entered into a long-term strategic partnership with a Swedish company, Probi AB, which develops and produces clinically proven probiotics.

As per the agreement, BLT would grant Probi a licence to manufacture and supply its key strains, BLIS K12™ and BLIS M18™. Moreover, BLT would issue new shares to provide 13% cornerstone shareholding to Probi.

Blis Technologies fell by 1.35% at NZ$0.073 by the end of the trading session on 9 July.

Read: What is the trading volume of 4 NZX stocks amid market session?

Fisher & Paykel Healthcare Corporation Limited (NZX:FPH)

Next in line is Fisher & Paykel Healthcare Corporation Limited. On 18 August, the Company will hold its Annual Meeting. Those shareholders who are willing to attend the meeting in person would be required to wear masks and practice physical distancing.

On 9 July, by the end of the trading session, Fisher & Paykel Healthcare Corporation was down by 1.20% at NZ$29.620.

Must Read: What is the NZX main board? A look at 10 NZX stocks

Pacific Edge Limited (NZX:PEB)

Lastly, we would look at Pacific Edge Limited, which is a cancer diagnostic company, which specialises in discovering and commercialising innovative cancer diagnostic tests. A recent study of significant importance revealed that the combined and sequential use of Cxbladder products attained 4.8 times greater efficiency in identifying haematuria patients as well as patients with high-impact tumours.

On 9 July, by the end of the trading session, Pacific Edge climbed by 0.81% at NZ$1.240.

Do Read: Pacific’s Cxbladder tests receive approval for use in public healthcare sector

Comment


Disclaimer

   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK